Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Therapy

Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children

Leukemia volume 21, pages 238–247 (2007)Cite this article

Abstract

The objective of the study was to assess acute neurotoxicity associated with triple intrathecal therapy (TIT)±high-dose methotrexate (HD MTX) in children with acute lymphoblastic leukemia (ALL). 1395 children were enrolled on FRALLE 93 protocol from 1993 to 1999. Lower-risk group (LR, n=182) were randomized to weekly low-dose MTX at 25 mg/m2/week (LD MTX, n=81) or HD MTX at 1.5 g/m2/2 weeks × 6 (n=77). Intermediate-risk group (IR, n=672) were randomized to LD MTX (n=290) or HD MTX at 8 g/m2/2 weeks × 4 (n=316). Higher-risk group (HR, n=541) prednisone-responder patients received LD MTX and cranial radiotherapy. HR group steroid resistant cases were grafted (autologous or allogenic). TIT (MTX, cytarabine and methylprednisolone) was given every 2 weeks during 16–18 weeks and every 3 months during maintenance therapy in LR and IR patients. 52 patients (3.7%) developed neurotoxicity. Isolated seizures: n=15 (1.1%), peripheral and spinal neuropathy: n=17 (1.2%) and encephalopathy: n=20 (1.4%). Age >10 years was significantly associated with neurotoxicity (P=0.01) and use of HD MTX is associated with encephalopathy (P=0.03). Sequels are reported respectively in 60 and 33% of spinal neuropathy and encephalopathy cases. Current strategies tailoring risk of neurological sequels has to be defined.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Balsom WR, Bleyer WA, Robison LL, Heyn RM, Meadows AT, Sitarz A et al. Intellectual function in long-term survivors of childhood acute lymphoblastic leukemia: protective effect of pre-irradiation methotrexate? A Childrens Cancer Study Group study. Med Pediatr Oncol 1991; 19: 486–492.

    Article  CAS  Google Scholar 

  2. Bleyer WA . Central nervous system leukemia. Pediatr Clin North Am 1988; 35: 789–814.

    Article  CAS  Google Scholar 

  3. Pui CH . Acute leukemia in children. Curr Opin Hematol 1996; 3: 249–258.

    Article  CAS  Google Scholar 

  4. Lauer SJ, Kirchner PA, Camitta BM . Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. Am J Pediatr Hematol Oncol 1989; 11: 64–73.

    Article  CAS  Google Scholar 

  5. Evans AE, Gilbert ES, Zandstra R . The increasing incidence of central nervous system leukemia in children. (Children's Cancer Study Group A). Cancer 1970; 26: 404–409.

    Article  CAS  Google Scholar 

  6. George SL, Ochs JJ, Mauer AM, Simone JV . The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. J Clin Oncol 1985; 3: 776–781.

    Article  CAS  Google Scholar 

  7. Unal S, Yetgin S, Cetin M, Gumruk F, Arslan D, Ozyurek E et al. The prognosis and survival of childhood acute lymphoblastic leukemia with central nervous system relapse. Pediatr Hematol Oncol 2004; 21: 279–289.

    Article  Google Scholar 

  8. Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J et al. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. J Clin Oncol 2006; 24: 3142–3149.

    Article  CAS  Google Scholar 

  9. Krance RA, Newman EM, Ravindranath Y, Harris MB, Brecher M, Wimmer R et al. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, ‘spread-out’ or ‘up-front, ‘ in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study. Cancer 1991; 67: 550–556.

    Article  CAS  Google Scholar 

  10. Pui CH, Relling MV, Campana D, Evans WE . Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol 2002; 6: 161–180; discussion 200–202.

    Article  CAS  Google Scholar 

  11. Ochs JJ . Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989; 11: 93–105.

    Article  CAS  Google Scholar 

  12. Reinders-Messelink HA, Van Weerden TW, Fock JM, Gidding CE, Vingerhoets HM, Schoemaker MM et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur J Paediatr Neurol 2000; 4: 225–233.

    Article  CAS  Google Scholar 

  13. Herzig RH, Hines JD, Herzig GP, Wolff SN, Cassileth PA, Lazarus HM et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol 1987; 5: 927–932.

    Article  CAS  Google Scholar 

  14. Resar LM, Phillips PC, Kastan MB, Leventhal BG, Bowman PW, Civin CI . Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer 1993; 71: 117–123.

    Article  CAS  Google Scholar 

  15. Mitchell LG, Sutor AH, Andrew M . Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment. Semin Thromb Hemost 1995; 21: 390–401.

    Article  CAS  Google Scholar 

  16. Nowak-Gottl U, Ahlke E, Fleischhack G, Schwabe D, Schobess R, Schumann C et al. Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration. Blood 2003; 101: 2529–2533.

    Article  CAS  Google Scholar 

  17. Yim YS, Mahoney Jr DH, Oshman DG . Hemiparesis and ischemic changes of the white matter after intrathecal therapy for children with acute lymphocytic leukemia. Cancer 1991; 67: 2058–2061.

    Article  CAS  Google Scholar 

  18. Ray M, Marwaha RK, Trehan A . Chemotherapy related fatal neurotoxicity during induction in acute lymphoblastic leukemia. Indian J Pediatr 2002; 69: 185–187.

    Article  Google Scholar 

  19. Kubo M, Azuma E, Arai S, Komada Y, Ito M, Sakurai M . Transient encephalopathy following a single exposure of high-dose methotrexate in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1992; 9: 157–165.

    Article  CAS  Google Scholar 

  20. Garcia-Tena J, Lopez-Andreu JA, Ferris J, Menor F, Mulas F, Millet E et al. Intrathecal chemotherapy-related myeloencephalopathy in a young child with acute lymphoblastic leukemia. Pediatr Hematol Oncol 1995; 12: 377–385.

    Article  CAS  Google Scholar 

  21. Gerrard MP, Eden OB, Lilleyman JS . Acute encephalopathy during induction therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol 1986; 3: 49–58.

    Article  CAS  Google Scholar 

  22. DiMario Jr FJ, Packer RJ . Acute mental status changes in children with systemic cancer. Pediatrics 1990; 85: 353–360.

    PubMed  Google Scholar 

  23. Winick NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D et al. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 1992; 84: 252–256.

    Article  CAS  Google Scholar 

  24. Pullen J, Boyett J, Shuster J, Crist W, Land V, Frankel L et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993; 11: 839–849.

    Article  CAS  Google Scholar 

  25. Mahoney Jr DH, Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ et al. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Cancer 1995; 75: 2623–2631.

    Article  Google Scholar 

  26. Bowman WP, Shuster JJ, Cook B, Griffin T, Behm F, Pullen J et al. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study. J Clin Oncol 1996; 14: 1252–1261.

    Article  CAS  Google Scholar 

  27. Mahoney Jr DH, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. J Clin Oncol 1998; 16: 1712–1722.

    Article  CAS  Google Scholar 

  28. Rubnitz JE, Relling MV, Harrison PL, Sandlund JT, Ribeiro RC, Rivera GK et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998; 12: 1176–1181.

    Article  CAS  Google Scholar 

  29. Shuper A, Stark B, Kornreich L, Cohen IJ, Aviner S, Steinmetz A et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. J Child Neurol 2000; 15: 573–580.

    Article  CAS  Google Scholar 

  30. Lo Nigro L, Di Cataldo A, Schiliro G . Acute neurotoxicity in children with B-lineage acute lymphoblastic leukemia (B-ALL) treated with intermediate risk protocols. Med Pediatr Oncol 2000; 35: 449–455.

    Article  CAS  Google Scholar 

  31. Packer RJ, Grossman RI, Belasco JB . High dose systemic methotrexate-associated acute neurologic dysfunction. Med Pediatr Oncol 1983; 11: 159–161.

    Article  CAS  Google Scholar 

  32. Allen JC, Rosen G, Mehta BM, Horten B . Leukoencephalopathy following high-dose iv methotrexate chemotherapy with leucovorin rescue. Cancer Treat Rep 1980; 64: 1261–1273.

    CAS  PubMed  Google Scholar 

  33. Quinn CT, Kamen BA . A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Investig Med 1996; 44: 522–530.

    CAS  PubMed  Google Scholar 

  34. Drachtman RA, Cole PD, Golden CB, James SJ, Melnyk S, Aisner J et al. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 2002; 19: 319–327.

    Article  CAS  Google Scholar 

  35. Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D et al. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol 2003; 21: 3084–3091.

    Article  CAS  Google Scholar 

  36. Jaffe N, Takaue Y, Anzai T, Robertson R . Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 1985; 56: 1356–1360.

    Article  CAS  Google Scholar 

  37. Defresne P, Hollenberg H, Husson B, Tabarki B, Landrieu P, Huault G et al. Acute transverse myelitis in children: clinical course and prognostic factors. J Child Neurol 2003; 18: 401–406.

    Article  Google Scholar 

  38. Ozon A, Topaloglu H, Cila A, Gunay M, Cetin M . Acute ascending myelitis and encephalopathy after intrathecal cytosine arabinoside and methotrexate in an adolescent boy with acute lymphoblastic leukemia. Brain Dev 1994; 16: 246–248.

    Article  CAS  Google Scholar 

  39. Wolff L, Zighelboim J, Gale RP . Paraplegia following intrathecal cytosine arabinoside. Cancer 1979; 43: 83–85.

    Article  CAS  Google Scholar 

  40. Watterson J, Toogood I, Nieder M, Morse M, Frierdich S, Lee Y et al. Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 1994; 74: 3034–3041.

    Article  CAS  Google Scholar 

  41. Pui CH, Mahmoud HH, Rivera GK, Hancock ML, Sandlund JT, Behm FG et al. Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 1998; 92: 411–415.

    CAS  PubMed  Google Scholar 

  42. Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. Blood 2006; 108: 1165–1173.

    Article  Google Scholar 

  43. Nicholson JC, Darmady JM, Kohler JA . Superior sagittal sinus thrombosis complicating maintenance treatment for acute lymphoblastic leukemia. Pediatr Hematol Oncol 1996; 13: 287–291.

    Article  CAS  Google Scholar 

  44. Chen CY, Zimmerman RA, Faro S, Bilaniuk LT, Chou TY, Molloy PT . Childhood leukemia: central nervous system abnormalities during and after treatment. AJNR Am J Neuroradiol 1996; 17: 295–310.

    CAS  PubMed  Google Scholar 

  45. Santoro N, Giordano P, Del Vecchio GC, Guido G, Rizzari C, Varotto S et al. Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study. J Pediatr Hematol Oncol 2005; 27: 153–157.

    Article  Google Scholar 

  46. deVeber G, Andrew M, Adams C, Bjornson B, Booth F, Buckley DJ et al. Cerebral sinovenous thrombosis in children. N Engl J Med 2001; 345: 417–423.

    Article  CAS  Google Scholar 

  47. Nowak-Gottl U, Schlegel N, Brenner B . New insights into paediatric haemostasis: thrombosis and bleeding issues. Thromb Haemost 2004; 92: 676–677.

    Article  Google Scholar 

Download references

Acknowledgements

We acknowledge David Young for editing. Preliminary report of the study has been reported at the annual meeting of the American Society of Hematology (ASH) in 1999 (Blood 1999, 94(10) (Suppl 1) 1285).

Author information

Authors and Affiliations

  1. Service d’hématologie et d’oncologie pédiatrique Hôpital d’Enfant Armand Trousseau, AP-HP, Paris,, France

    M N Dufourg, J Landman-Parker, M D Tabone & G Leverger

  2. Service d’hématologie pédiatrique Hôpital St Louis, AP-HP, Paris, France

    M F Auclerc, T Leblanc & A Baruchel

  3. Service de pédiatrie II hospital d’Enfant Vandoeuvre les Nancy, Paris, France

    C Schmitt

  4. Département de pédiatrie CHU Pellerin Bordeaux, Paris, France

    Y Perel

  5. Service d’hématologie pédiatrique CHU La Timone, Marseille, Paris, France

    G Michel

  6. Département d’informatique médicale Hôpital Tenon, AP-HP, Paris, France

    P Levy

  7. Service de pédiatrie CHR de Limoges,

    G Couillault

  8. Service de pédiatrie CHR Rennes,

    V Gandemer

  9. Service d’hématologie CHR Clermont Ferrand,

    F Demeocq

  10. Département de pédiatrie CHR Rouen, for the French cooperative group FRALLE,

    J P Vannier

Authors
  1. M N Dufourg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Landman-Parker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M F Auclerc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y Perel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Michel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Couillault
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. V Gandemer
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M D Tabone
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F Demeocq
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J P Vannier
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. T Leblanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G Leverger
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. A Baruchel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Landman-Parker.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Dufourg, M., Landman-Parker, J., Auclerc, M. et al. Age and high-dose methotrexate are associated to clinical acute encephalopathy in FRALLE 93 trial for acute lymphoblastic leukemia in children. Leukemia 21, 238–247 (2007). https://doi.org/10.1038/sj.leu.2404495

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404495

Keywords

  • neurotoxicity
  • acute lymphoblastic leukemia
  • pediatric

This article is cited by

Search

Advanced search

Quick links